The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1 University of Melbourne, Melbourne, VIC
- 2 Peninsula Health, Melbourne, VIC
- 3 Austin Health, Melbourne, VIC
Correspondence: JNg@phcn.vic.gov.au
Acknowledgements:
We thank Helen Baxter and Shanti Nadaraja (Austin Health Sciences Library, Austin Health) for expert assistance with the structured literature searches.
Competing interests:
No relevant disclosures.
- 1. Patrono C. Aspirin: new cardiovascular uses for an old drug. Am J Med 2001; 110 (Suppl 1A): 62S-65S.
- 2. Taha AS, Angerson WJ, Knill-Jones RP, et al. Upper gastrointestinal haemorrhage associated with low-dose aspirin and anti-thrombotic drugs: a 6-year analysis and comparison with non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2005; 22: 285-289.
- 3. Taha AS, Angerson WJ, Prasad R, et al. Upper gastrointestinal bleeding and the changing use of COX-2 non-steroidal anti-inflammatory drugs and low-dose aspirin. Aliment Pharmacol Ther 2007; 26: 1171-1178.
- 4. Lanza FL, Chan FK, Quigley EM, et al. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol 2009; 104: 728-738.
- 5. Lanas A. Gastrointestinal bleeding associated with low-dose aspirin use: relevance and management in clinical practice. Expert Opin Drug Saf 2011; 10: 45-54.
- 6. Fletcher EH, Johnston DE, Fisher CR, et al. Helicobacter pylori and the risk of upper gastrointestinal bleeding risk in patients taking aspirin. Aliment Pharmacol Ther 2010; 32: 831-839.
- 7. Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2008; 52: 1502-1517.
- 8. Chey WD, Leontiadis GI, Howden CW, et al. ACG clinical guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol 2017; 112: 212-238.
- 9. Patrono C. Aspirin as an antiplatelet drug. N Engl J Med 1994; 330: 1287-1294.
- 10. Chan FK, Chung SC, Suen BY, et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 2001; 344: 967-973.
- 11. Chan FK, Ching JY, Suen BY, et al. Effects of Helicobacter pylori infection on long-term risk of peptic ulcer bleeding in low-dose aspirin users. Gastroenterology 2013; 144: 528-535.
- 12. Lai KC, Lam SK, Chu KM, et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med 2002; 346: 2033-2038.
- 13. Goodwin CS, Armstrong JA, Chilvers T, et al. Transfer of Campylobacter pylori and Campylobacter mustelae to Helicobacter gen. nov. as Helicobacter pylori comb. nov. and Helicobacter mustelae comb. nov. respectively. Int J Syst Bacteriol 1989; 39: 397-405.
- 14. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009; 151: 264-269.
- 15. Wells GA, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses [webpage]. 2011. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp (viewed Dec 2017).
- 16. Cullen DJ, Hawkey GM, Greenwood DC, et al. Peptic ulcer bleeding in the elderly: relative roles of Helicobacter pylori and non-steroidal anti-inflammatory drugs. Gut 1997; 41: 459-462.
- 17. Aalykke CL, Lauritsen JM, Hallas J, et al. Helicobacter pylori and risk of ulcer bleeding among users of nonsteroidal anti-inflammatory drugs: a case–control study. Gastroenterology 1999; 116: 1305-1309.
- 18. Santolaria S, Lanas A, Benito R, et al. Helicobacter pylori infection is a protective factor for bleeding gastric ulcers but not for bleeding duodenal ulcers in NSAID users. Aliment Pharmacol Ther 1999; 13: 1511-1518.
- 19. Lanas A, Fuentes J, Benito R, et al. Helicobacter pylori increases the risk of upper gastrointestinal bleeding in patients taking low-dose aspirin. Aliment Pharmacol Ther 2002; 16: 779-786.
- 20. Udd M, Miettinen P, Palmu A, et al. Analysis of the risk factors and their combinations in acute gastroduodenal ulcer bleeding: a case–control study. Scand J Gastroenterol 2007; 42: 1395-1403.
- 21. Shiotani A, Murao T, Fujita Y, et al. Single nucleotide polymorphism markers for low-dose aspirin-associated peptic ulcer and ulcer bleeding. J Gastroenterol Hepatol 2014; 29 (Suppl 4): 47-52.
- 22. Sostres C, Carrera-Lasfuentes P, Benito R, et al. Peptic ulcer bleeding risk: the role of Helicobacter pylori infection in NSAID/low-dose aspirin users. Am J Gastroenterol 2015; 110: 684-689.
- 23. Czernichow P, Hochain P, Nousbaum J-B, et al. Epidemiology and course of acute upper gastro-intestinal haemorrhage in four French geographical areas. Eur J Gastroenterol Hepatol 2000; 12: 175-181.
- 24. Hayden M, Pignone M, Phillips C, et al. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the US Preventive Services Task Force. Ann Intern Med 2002; 136: 161-172.
- 25. Serrano P, Lanas A, Arroyo MT, et al. Risk of upper gastrointestinal bleeding in patients taking low-dose aspirin for the prevention of cardiovascular diseases. Aliment Pharmacol Ther 2002; 16: 1945-1953.
- 26. Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 2002; 359: 14-22.
- 27. Zeitoun J-D, Rosa-Hézode I, Chryssostalis A, et al. Epidemiology and adherence to guidelines on the management of bleeding peptic ulcer: a prospective multicenter observational study in 1140 patients. Clin Res Hepatol Gastroenterol 2012; 36: 227-234.
- 28. Zullo A, Hassan C, Oliveti D, et al. Helicobacter pylori management in non-steroidal anti-inflammatory drug therapy patients in primary care. Intern Emerg Med 2012; 7: 331-335.
- 29. Velasco-Zamora JA, Gómez-Reyes E, Uscanga L. Are the clinical guideline recommendations on gastroprotection being followed? A review in patients taking nonsteroidal anti-inflammatory drugs. Rev Gastroenterol Mex 2016; 81: 121-125.
- 30. Lanas A, García-Rodríguez LA, Arroyo MT, et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut 2006; 55: 1731-1738.
- 31. Tielleman T, Bujanda D, Cryer B. Epidemiology and risk factors for upper gastrointestinal bleeding. Gastrointest Endosc Clin N Am 2015; 25: 415-428.
- 32. Iser DM, Thompson AJV, Sia KK, et al. Prospective study of cardiac troponin I release in patients with upper gastrointestinal bleeding. J Gastroenterol Hepatol 2008; 23: 938-942.
- 33. Wang T, Zhang Y, Su H, et al. Helicobacter pylori antibody responses in association with eradication outcome and recurrence: a population-based intervention trial with 7.3-year follow-up in China. Chin J Cancer Res 2017; 29: 127-136.
- 34. Fallone CA, Loo VG, Barkun AN. Utility of serology in determining Helicobacter pylori eradication after therapy. Can J Gastroenterol 1998; 12: 117-124.
- 35. Biranjia-Hurdoyal SD, Seetulsingh-Goorah SP. Performances of four Helicobacter pylori serological detection kits using stool antigen test as gold standard. PLoS One 2016; 11: e0163834.
- 36. Moss SF. The clinical evidence linking Helicobacter pylori to gastric cancer. Cell Mol Gastroenterol Hepatol 2017; 3: 183-191.
Online responses are no longer available. Please refer to our instructions for authors page for more information.
Abstract
Objective: To determine whether the risk of upper gastrointestinal bleeding in patients taking low dose aspirin (≤ 325 mg/day) is increased in people with Helicobacter pylori infections.
Study design: A systematic search for all publications since 1989 (when H. pylori was named) using search term equivalents for “upper gastrointestinal haemorrhage” and “aspirin”. Articles were assessed individually for inclusion of data on H. pylori infection, as not all relevant papers were indexed with this term. Data that could be pooled were then subjected to meta-analysis, using a random effects model.
Data sources: MEDLINE, Embase, Scopus, the Cochrane Library.
Data synthesis: Of 7599 retrieved publications, reports for seven case–control studies contained data suitable for meta-analysis; four were deemed high quality on the Newcastle–Ottawa scale. Upper gastrointestinal haemorrhage was more frequent in aspirin users infected with H. pylori than in those who were not (odds ratio [OR], 2.32; 95% CI, 1.25–4.33; P = 0.008). The heterogeneity of the studies was significant (Q = 19.3, P = 0.004; I2 = 68.9%, 95% CI, 31.5–85.9%), but the pooled odds ratio was similar after removing the two studies that contributed most to heterogeneity (OR, 2.34; 95% CI, 1.56–3.53; P < 0.001). The number needed to treat to prevent one bleeding event annually was estimated to be between 100 and more than 1000.
Conclusions: The odds of upper gastrointestinal bleeding in patients taking low dose aspirin is about twice as great in those infected with H. pylori. Testing for and treating the infection should be considered in such patients, especially if their underlying risk of peptic ulcer bleeding is already high.